EGFR and hepatocellular carcinoma: Preclinical in vivo studies using patient-derived xenografts demonstrated therapeutic benefits of a combination of lenvanitib and EGFR inhibitor gefitinib, followed by a small clinical trial using 12 lenvatinib-unresponsive advanced HCC patients, who showed meaningful clinical responses with the lenvatinib and gefitinib combination [38].